Assay development is currently underway by our contract development partner Thermo Fisher Scientific to transfer the research assay to Luminex® instrumentation. Clinical studies are then expected to commence in 2H19 for both BARD1-Breast and BARD1-Ovarian to evaluate clinical performance with expected launch as Laboratory Developed Tests (LDTs) in 2021.
The Company's business strategy is to leverage its BARD1 Technology to develop diagnostic tests for early detection of cancer when it can be potentially cured. The Company plans to develop a portfolio of non-invasive diagnostic tests for early detection, diagnosis or monitoring of cancer, conduct clinical studies to demonstrate the clinical performance of its BARD1 Tests and enable medical device marketing, and then commercialise its products through licensing its diagnostic tests to clinical laboratory, major diagnostic or biopharmaceutical partners in the USA, Europe and Asia.
I do recall reading that applications for FDA approval will follow at some point after licencing it's diagnostic tests through partnership/s as stated above..
- Forums
- ASX - By Stock
- IIQ
- BD1
BD1, page-17
-
- There are more pages in this discussion • 1,088 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
(20min delay)
|
|||||
Last
48.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $53.53M |
Open | High | Low | Value | Volume |
48.0¢ | 48.0¢ | 48.0¢ | $5.475K | 11.40K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 48.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
49.0¢ | 310 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 0.480 |
3 | 29208 | 0.475 |
3 | 39544 | 0.470 |
3 | 13650 | 0.465 |
5 | 57892 | 0.460 |
Price($) | Vol. | No. |
---|---|---|
0.490 | 310 | 1 |
0.495 | 7917 | 1 |
0.500 | 20153 | 2 |
0.505 | 28000 | 3 |
0.510 | 20000 | 2 |
Last trade - 11.22am 02/10/2024 (20 minute delay) ? |
Featured News
IIQ (ASX) Chart |